{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T02:44:19Z","timestamp":1775011459792,"version":"3.50.1"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T00:00:00Z","timestamp":1571875200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"German council foundation"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0223893","type":"journal-article","created":{"date-parts":[[2019,10,24]],"date-time":"2019-10-24T17:31:34Z","timestamp":1571938294000},"page":"e0223893","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":6,"title":["Impact of faecal calprotectin measurement on clinical decision-making in patients with Crohn\u2019s disease and ulcerative colitis"],"prefix":"10.1371","volume":"14","author":[{"given":"Anna Luisa","family":"Bathe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eirini","family":"Mavropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolae-Catalin","family":"Mechie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Golo","family":"Petzold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Volker","family":"Ellenrieder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steffen","family":"Kunsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0801-2087","authenticated-orcid":true,"given":"Ahmad","family":"Amanzada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,10,24]]},"reference":[{"key":"pone.0223893.ref001","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.crohns.2013.02.014","article-title":"Concept for a rapid point-of-care calprotectin diagnostic test for diagnosis and disease activity monitoring in patients with inflammatory bowel disease: Expert clinical opinion","volume":"7","author":"G Rogler","year":"2013","journal-title":"J Crohns Colitis"},{"key":"pone.0223893.ref002","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1097\/MIB.0000000000001082","article-title":"Clinical Utility of Fecal Calprotectin Monitoring in Asymptomatic Patients with Inflammatory Bowel Disease: A Systematic Review and Practical Guide","volume":"23","author":"A Heida","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"pone.0223893.ref003","doi-asserted-by":"crossref","first-page":"V1","DOI":"10.1136\/gut.2004.043372","article-title":"Guidelines for the management of inflammatory bowel disease in adults","volume":"53","author":"MJ Carter","year":"2004","journal-title":"Gut"},{"key":"pone.0223893.ref004","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1097\/MIB.0000000000000057","article-title":"Meta-analysis: Fecal Calprotectin for Assessment of Inflammatory Bowel Disease Activity","volume":"20","author":"JF Lin","year":"2014","journal-title":"Inflamm Bowel Dis"},{"key":"pone.0223893.ref005","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/j.crohns.2012.09.003","article-title":"Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 1: Definitions and diagnosis","volume":"6","author":"A Dignass","year":"2012","journal-title":"J Crohns Colitis"},{"key":"pone.0223893.ref006","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.crohns.2009.12.003","article-title":"The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis","volume":"4","author":"G Van Assche","year":"2010","journal-title":"J Crohns Colitis"},{"key":"pone.0223893.ref007","doi-asserted-by":"crossref","first-page":"299","DOI":"10.15403\/jgld.2014.1121.273.pti","article-title":"Fecal Calprotectin in Assessing Inflammatory Bowel Disease Endoscopic Activity: a Diagnostic Accuracy Meta-analysis","volume":"27","author":"T Rokkas","year":"2018","journal-title":"J Gastrointestin Liver Dis"},{"key":"pone.0223893.ref008","doi-asserted-by":"crossref","first-page":"6782","DOI":"10.3748\/wjg.v18.i46.6782","article-title":"Utility of faecal calprotectin analysis in adult inflammatory bowel disease","volume":"18","author":"LA Smith","year":"2012","journal-title":"World J Gastroenterol"},{"key":"pone.0223893.ref009","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.3748\/wjg.v24.i33.3681","article-title":"From bench to bedside: Fecal calprotectin in inflammatory bowel diseases clinical setting","volume":"24","author":"MG Mumolo","year":"2018","journal-title":"World J Gastroenterol"},{"key":"pone.0223893.ref010","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/00365529950172835","article-title":"Correlation between Faecal Excretion of Indium-111-Labelled Granulocytes and Calprotectin, a Granulocyte Marker Protein, in Patients with Inflammatory Bowel Disease","volume":"34","author":"AG R\u00f8seth","year":"1999","journal-title":"Scand J Gastroenterol"},{"key":"pone.0223893.ref011","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/imj.14027","article-title":"Faecal calprotectin delivers on convenience, cost reduction and clinical decision making in inflammatory bowel disease: a real world cohort study","volume":"49","author":"S Motaganahalli","year":"2019","journal-title":"Intern Med J"},{"key":"pone.0223893.ref012","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1111\/apt.12221","article-title":"A prospective single-centre evaluation of the intra-individual variability of faecal calprotectin in quiescent Crohn's disease","volume":"37","author":"GD Naismith","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0223893.ref013","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1572-0241.2007.01556.x","article-title":"Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices","volume":"103","author":"J Langhorst","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"pone.0223893.ref014","doi-asserted-by":"crossref","first-page":"8235","DOI":"10.3748\/wjg.v23.i46.8235","article-title":"Efficacy of noninvasive evaluations in monitoring inflammatory bowel disease activity: A prospective study in China","volume":"23","author":"JM Chen","year":"2017","journal-title":"World J Gastroenterol"},{"key":"pone.0223893.ref015","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3748\/wjg.14.53","article-title":"Clinical value of fecal calprotectin in determining disease activity of ulcerative colitis","volume":"14","author":"JY Xiang","year":"2008","journal-title":"World J Gastroenterol"},{"key":"pone.0223893.ref016","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1002\/ibd.22917","article-title":"Fecal Calprotectin is a Surrogate Marker for Endoscopic Lesions in Inflammatory Bowel Disease","volume":"18","author":"G D'Haens","year":"2012","journal-title":"Inflamm Bowel Dis"},{"key":"pone.0223893.ref017","doi-asserted-by":"crossref","first-page":"13566","DOI":"10.3748\/wjg.v21.i48.13566","article-title":"Fecal calprotectin correlated with endoscopic remission for Asian inflammatory bowel disease patients","volume":"21","author":"WC Lin","year":"2015","journal-title":"World J Gastroenterol"},{"key":"pone.0223893.ref018","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/jgh3.12068","article-title":"Fecal calprotectin correlates with active colonic inflammatory bowel disease but not with small intestinal Crohn's disease activity","volume":"2","author":"E Zittan","year":"2018","journal-title":"JGH Open"},{"key":"pone.0223893.ref019","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/ajg.2015.120","article-title":"C-Reactive Protein, Fecal Calprotectin, and Stool Lactoferrin for Detection of Endoscopic Activity in Symptomatic Inflammatory Bowel Disease Patients: A Systematic Review and Meta-Analysis","volume":"110","author":"MH Mosli","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"pone.0223893.ref020","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/gut.2004.043406","article-title":"Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease","volume":"54","author":"F Costa","year":"2005","journal-title":"Gut"},{"key":"pone.0223893.ref021","unstructured":"IBD Clinic. Modified Harvey Bradshaw Index Assessment for Crohn\u2019s Disease Activity. http:\/\/www.ibdclinic.ca\/media\/uploads\/harvey_bradshaw_index_09_2016.pdf Cited 15.01.2019."},{"key":"pone.0223893.ref022","unstructured":"IBD Clinic. Partial Mayo Scoring Index Assessment for Ulcerative Colitis Activity. http:\/\/www.ibdclinic.ca\/media\/uploads\/partial_mayo_09_2016.pdf Cited 15.01.2019."},{"key":"pone.0223893.ref023","doi-asserted-by":"crossref","first-page":"5A","DOI":"10.1155\/2005\/269076","article-title":"Toward an Integrated Clinical, Molecular and Serological Classification of Inflammatory Bowel Disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology","volume":"19","author":"MS Silverberg","year":"2005","journal-title":"Can J Gastroenterol"},{"key":"pone.0223893.ref024","first-page":"1359","article-title":"Knowledge of Fecal Calprotectin and Infliximab Trough Levels Alters Clinical Decision-making for IBD Outpatients on Maintenance Infliximab Therapy","volume":"21","author":"VW Huang","year":"2015","journal-title":"Inflamm Bowel Dis"},{"key":"pone.0223893.ref025","doi-asserted-by":"crossref","first-page":"8211","DOI":"10.3748\/wjg.v22.i36.8211","article-title":"FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease","volume":"22","author":"G Rosenfeld","year":"2016","journal-title":"World J Gastroenterol"},{"key":"pone.0223893.ref026","doi-asserted-by":"crossref","first-page":"2483261","DOI":"10.1155\/2016\/2483261","article-title":"The Utility of Fecal Calprotectin in the Real-World Clinical Care of Patients with Inflammatory Bowel Disease","volume":"2016","author":"E Abej","year":"2016","journal-title":"Can J Gastroenterol Hepatol"},{"key":"pone.0223893.ref027","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3389\/fped.2017.00007","article-title":"Impact of Fecal Calprotectin Measurement on Decision-making in Children with Inflammatory Bowel Disease","volume":"5","author":"W El-Matary","year":"2017","journal-title":"Front Pediatr"},{"key":"pone.0223893.ref028","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/1756283X17744739","article-title":"Factors affecting clinical decision-making in inflammatory bowel disease and the role of point-of-care calprotectin","volume":"11","author":"Y Derwa","year":"2018","journal-title":"Therap Adv Gastroenterol"},{"key":"pone.0223893.ref029","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target","volume":"110","author":"L Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"pone.0223893.ref030","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/ncpgasthep0359","article-title":"The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases","volume":"2","author":"S Vermeire","year":"2005","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"pone.0223893.ref031","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1136\/gut.27.7.809","article-title":"Differing acute phase responses in Crohn's disease and ulcerative colitis","volume":"27","author":"SH Saverymuttu","year":"1986","journal-title":"Gut"},{"key":"pone.0223893.ref032","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.cgh.2015.06.001","article-title":"Defining Disease Severity in Inflammatory Bowel Diseases: Current and Future Directions","volume":"14","author":"L Peyrin-Biroulet","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"pone.0223893.ref033","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2036.2011.04710.x","article-title":"Systematic review: the use of ultrasonography, computed tomography and magnetic resonance imaging for the diagnosis, assessment of activity and abdominal complications of Crohn's disease","volume":"34","author":"J Pan\u00e9s","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"pone.0223893.ref034","doi-asserted-by":"crossref","first-page":"292","DOI":"10.3389\/fped.2017.00292","article-title":"The Value of Fecal Markers in Predicting Relapse in Inflammatory Bowel Diseases","volume":"5","author":"BJ Galgut","year":"2018","journal-title":"Front Pediatr"},{"key":"pone.0223893.ref035","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1053\/j.gastro.2015.01.026","article-title":"Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn's Disease After Surgery","volume":"148","author":"EK Wright","year":"2015","journal-title":"Gastroenterology"},{"key":"pone.0223893.ref036","doi-asserted-by":"crossref","first-page":"2779","DOI":"10.1016\/S0140-6736(17)32641-7","article-title":"Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial","volume":"390","author":"JF Colombel","year":"2017","journal-title":"Lancet"},{"key":"pone.0223893.ref037","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1038\/ajg.2009.672","article-title":"Are Colonoscopy and Bowel Ultrasound Useful for Assessing Response to Short-Term Therapy and Predicting Disease Outcome of Moderate-to-Severe Forms of Ulcerative Colitis?: A Prospective Study","volume":"105","author":"F Parente","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"pone.0223893.ref038","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1097\/MIB.0b013e31829b2a37","article-title":"Consecutive fecal calprotectin measurements to predict relapse in patients with ulcerative colitis receiving infliximab maintenance therapy","volume":"19","author":"M De Vos","year":"2013","journal-title":"Inflamm Bowel Dis"},{"key":"pone.0223893.ref039","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1007\/s00053-014-0464-7","article-title":"Klinik, CRP, Calprotectin, MRT oder Endoskopie? Strategien zur sinnvollen Therapie\u00fcberwachung bei CED","volume":"36","author":"M Prager","year":"2014","journal-title":"coloproctology"},{"key":"pone.0223893.ref040","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12876-017-0669-7","article-title":"Fecal calprotectin predicts complete mucosal healing and better correlates with the ulcerative colitis endoscopic index of severity than with the Mayo endoscopic subscore in patients with ulcerative colitis","volume":"17","author":"SH Lee","year":"2017","journal-title":"BMC Gastroenterol"},{"key":"pone.0223893.ref041","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1053\/j.gastro.2015.09.001","article-title":"Correlation Between Concentrations of Fecal Calprotectin and Outcomes of Patients With Ulcerative Colitis in a Phase 2 Trial","volume":"150","author":"WJ Sandborn","year":"2016","journal-title":"Gastroenterology"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0223893","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,26]],"date-time":"2021-01-26T01:05:39Z","timestamp":1611623139000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0223893"}},"subtitle":[],"editor":[{"given":"Bruno","family":"Bonaz","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,10,24]]},"references-count":41,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2019,10,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0223893","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,24]]}}}